Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Funmi Olopade, MD
November 20th 2021

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

Hayden E. Klein
Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.
Matt Dickson
November 7th 2021

Contributor: Don’t Delay—Why Now Is the Time to Reengage Patients in Routine Cancer Screenings

Matt Dickson
Ignoring life-threatening, non–COVID-19 conditions for too long can turn one health crisis into another. Now is the time to resume cancer screenings, like mammograms and colonoscopies, because early detection can be lifesaving.
Cells being irradiated
October 3rd 2021

Consolidative Radiation Therapy Improves Progression-Free Survival in DLBCL

Deanna Ferreri, PhD
This new study shows that consolidative radiation therapy may be of benefit to persons with diffuse large B-cell lymphoma, both bulky and nonbulky disease.
Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model
October 1st 2021

Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model

The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
Elizabeth Kwo, MD, MBA, MPH, deputy chief clinical officer at Anthem BCBS, a
September 29th 2021

Dr Elizabeth Kwo on Using Predictive Analytics to Curb Avoidable Hospitalizations During Cancer Therapy

Anemia, fevers, dehydration, and other side effects from cancer treatment are all candidates for targeting with predictive analytics in an effort to care for patients are home instead of the hospital, said Elizabeth Kwo, MD, MBA, MPH, the deputy chief clinical officer at Anthem BCBS, and a speaker at the 10th anniversary of Patient-Centered Oncology Care® conference.
Advances in Understanding of DLBCL Offer Prognostic and Theraptic Value
September 26th 2021

Surface Proteins in DLBCL Offer Therapeutic Targets

Deana Ferreri, PhD
Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.
Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status
September 19th 2021

Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status

Mary Caffrey
Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.
In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1
September 19th 2021

In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1

Mary Caffrey
The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”
Young woman undergoing chemotherapy with physician.
September 14th 2021

Spotlighting Social, Emotional Needs in Underserved Populations With Cancer

Matthew Gavidia
Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.
Gary Lyman, MD, MPH
September 8th 2021

Dr Gary Lyman: Pandemic Barriers Led to More Late-Stage Cancer Presentations

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how doctors are managing patients who present with later-stage cancers as a result of barriers to screening measures imposed by the pandemic.
Study: PET/CT Scans Predict for Response in Salvage Stage DLBCL
September 5th 2021

Study: PET/CT Scans Predict for Response in Salvage-Stage DLBCL

Tony Hagen
For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.
A Review of Standard of Care in DLBCL
August 29th 2021

A Review of Standard of Care in DLBCL

Tony Hagen
A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.
Genomic Complexity Linked With Poor Outcomes in DLBCL
August 16th 2021

Genomic Complexity Linked With Poor Outcomes in DLBCL

Jared Kaltwasser
A new report could eventually help investigators better understand which patients with diffuse large B-cell lymphoma (DLBCL) are most likely to respond to certain therapies.
Physician and patient.
August 13th 2021

High-Dose Methotrexate Effective in Preventing Isolated CNS Relapse in Diffuse Large B-Cell Lymphoma

Matthew Gavidia
Risk of isolated central nervous system (CNS) involvement was found to be significantly lower in patients with diffuse large B-cell lymphoma who received high-dose methotrexate vs RCHOP chemotherapy, although risk of concomitant CNS-systemic relapse rates were similar between both groups.
image of cancer cells
August 11th 2021

Meta-Analysis Finds CIT Regimens Associated With Improved Survival, Safety Outcomes in NSCLC

Jaime Rosenberg
Due to the lack of head-to-head trials comparing chemoimmunotherapy regimens with chemotherapy alone as first-line treatment for non-small cell lung cancer, researchers conducted a network meta-analysis of 17 randomized controlled trials of patients with the cancer.
Diversity in a group of people.
August 1st 2021

An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations

Matthew Gavidia
On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.
Long-term Survival Trends Among AYAs With the Highest Mortality Cancer Types
July 30th 2021

Long-term Survival Trends Among AYAs With the Highest Mortality Cancer Types

Laura Joszt, MA
Long-term survival trends among adolescents and young adults (AYAs) with the cancer types with the highest mortality highlight areas where additional research is needed.
health care cost
July 23rd 2021

Addressing Financial Toxicity With Patients and Health Systems

Laura Joszt, MA
Speakers at the Advanced Topics for Oncology Pharmacy Professionals Summit discussed financial toxicity in health care, how it particularly impacts patients with cancer, and how to address the issue with patients and the health system.
ASTRO logo
July 20th 2021

CMS Seeks Changes to Radiation Oncology Model; ASTRO Responds

Mary Caffrey
Due to unprecedented disruption and missed screenings during the pandemic, efforts to implement a 5-year performance period under the Radiation Oncology Model were extended twice.
Todd Schlesinger, MD, FAAD, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas
July 16th 2021

Dr Todd Schlesinger: Surgical Decisions for Skin Cancer Are Multimodal

Maggie L. Shaw
The characteristics of the tumor and the presence of surgical fatigue can help determine patients’ candidacy for skin cancer surgery, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
ASCO, COA Release Updated Standards for Oncology Medical Home
July 13th 2021

ASCO, COA Release Updated Standards for Oncology Medical Home

Mary Caffrey
The new standards come as community oncology practices await word on the future of the oncology care model, which will expire in 2022.
stethoscope on American flag
July 8th 2021

Obesity, Disparities, and Treatment Advancements Shape US Cancer Trends

Gianna Melillo
New data underscore how obesity, racial disparities and recent treatment advancements have impacted cancer mortality and incidence rates.
Bright idea
July 1st 2021

Next-Generation Oncology APMs Need More Planning to Succeed

Maggie L. Shaw
Originally set to expire on June 30, 2021, the Oncology Care Model was extended for an additional year in light of the COVID-19 pandemic.
Weidner et al, Appendices
June 21st 2021

Weidner et al, Appendices

Susan Weidner, MBA, MS Michael Diaz, MD Cass Schaedig Lucio Gordan, MD
Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology
Real-World Evidence Is Key to Accelerating Oncology Approvals
June 21st 2021

Real-World Evidence Is Key to Accelerating Oncology Approvals

Jennifer B. Christian, PharmD, MPH, PhD
A Social Worker Leads ACCC, and Her Timing Is Perfect
June 19th 2021

A Social Worker Leads ACCC, and Her Timing Is Perfect

Mary Caffrey
Phase 2 Data for Tisagenlecleucel, Tafasitamab Show Objective Responses in More Than Half of Patients
June 19th 2021

Phase 2 Data for Tisagenlecleucel, Tafasitamab Show Objective Responses in More Than Half of Patients

Jared Kaltwasser
Both sets of data were unveiled at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held earlier this month in a virtual format.
woman with bonnet laying in bed receiving IV in her hand
June 16th 2021

Oncology Roundup: Conference Presentations Illustrate Impact of New Cancer Therapies

Skylar Jeremias
Three recent conferences yielded new data on which treatment therapies are providing substantial benefits to patients and which ones are demonstrating more lackluster results.
FDA logo
June 10th 2021

FDA Issues Updated Guidance for PROs in Cancer Trials

Gianna Melillo
New FDA guidance includes updates for assessing patient-reported outcomes in cancer trials.
Image of Black female patient in a cancer center
June 9th 2021

Community-Based Initiative Doubles Accrual Rate of Black Participants in Cancer Trials

Lauren Massaro
An initiative launched with the intent to deliver equitable cancer care improved the enrollment rates of Black participants in cancer clinical trials by focusing on community outreach and engagement.
<1
...
121314151617181920
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo